These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19719455)

  • 21. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
    Zhang X
    Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone directed therapies for prostate cancer.
    Bradley DA; Hussain M; Dipaola RS; Kantoff P
    J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling.
    Mancini A; Colapietro A; Pompili S; Del Fattore A; Delle Monache S; Biordi LA; Angelucci A; Mattei V; Liang C; Gravina GL; Festuccia C
    Tumour Biol; 2018 Apr; 40(4):1010428318771773. PubMed ID: 29687745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis.
    Hagaman DE; Damasco JA; Perez JVD; Rojo RD; Melancon MP
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33450939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs for the treatment of bone metastasis.
    Pantano F; Iuliani M; Zoccoli A; Fioramonti M; De Lisi D; Fioroni I; Ribelli G; Santoni M; Vincenzi B; Tonini G; Santini D
    Expert Opin Emerg Drugs; 2015; 20(4):637-51. PubMed ID: 26113304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging therapeutic targets in breast cancer bone metastasis.
    Rose AA; Siegel PM
    Future Oncol; 2010 Jan; 6(1):55-74. PubMed ID: 20021209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metastatic hormone refractory prostate cancer: new treatment horizon].
    Keizman D; Maimon N; Gottfried M
    Harefuah; 2012 Sep; 151(9):545-9, 555, 554. PubMed ID: 23367751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment.
    Eaton CL; Coleman RE
    Cancer Treat Rev; 2003 Jun; 29(3):189-98. PubMed ID: 12787713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
    Sudhan DR; Pampo C; Rice L; Siemann DW
    Int J Cancer; 2016 Jun; 138(11):2665-77. PubMed ID: 26757413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.
    Hiraga T
    Expert Opin Investig Drugs; 2016; 25(3):319-34. PubMed ID: 26778342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Src as a therapeutic target in men with prostate cancer and bone metastases.
    Saad F
    BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
    Cheung FY
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():13-15. PubMed ID: 30489032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
    Dorff TB; Agarwal N
    Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.
    Chirgwin JM; Guise TA
    J Cell Biochem; 2007 Dec; 102(6):1333-42. PubMed ID: 17907152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and future treatments of bone metastases.
    Clark JC; Dass CR; Choong PF
    Expert Opin Emerg Drugs; 2008 Dec; 13(4):609-27. PubMed ID: 19046130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.